Bordeaux, France / March 1st, 2022 – TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need
Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab, and pembrolizumab
5th designation received by Celularity within 12 months from the US FDA
EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies
Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies. [Read more…]
Exopharm Signs Master Collaborative Agreement to Manufacture Exosomes for Astellas
-
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company
-
Initial services will seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA
-
Future potential collaboration is anticipated following validation
-
This is Exopharm’s first collaboration services agreement with a major pharmaceutical company
StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke
StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
StemCyte is a portfolio company of Microbio Group focusing on new drug discovery in cell therapy with operations in the U.S., Taiwan, and India
BALDWIN PARK, Calif., Jan. 26, 2022 — Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB). [Read more…]
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 146
- Next Page »